Synaf­fix ex­pands ADC deal from 2022 with Macro­Gen­ics

The Dutch biotech Synaf­fix, which has been ac­tive in the deal space out of the gate in 2023, is build­ing on a deal it made with Macro­Gen­ics last year.

Synaf­fix an­nounced Tues­day it has ex­pand­ed an agree­ment with the biotech Macro­Gen­ics to li­cense out its an­ti­body con­ju­ga­tion plat­form, called Gly­co­Con­nect, along with oth­er pieces of Synaf­fix’s tech­nol­o­gy. The deal is de­signed to cre­ate sev­er­al ADC pro­grams. Both com­pa­nies inked the first in Feb­ru­ary 2022, which net­ted Synaf­fix $586 mil­lion in up­front and mile­stone pay­ments, with three pro­grams be­ing de­vel­oped. Synaf­fix is el­i­gi­ble for roy­al­ties on com­mer­cial sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER